Bristol Myers Squibb stock, Thursday chart and analyst focus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 13:06.

Bristol Myers Squibb (US0897961004) opens Thursday with the broader U.S. tape still mixed, while the company trades on the NYSE and the S&P 500 and Nasdaq 100 both finished lower in the latest broad-market read.

Thursday chart backdrop

The broad market tone matters for Bristol Myers Squibb shares because the latest session left the S&P 500 down 0.10 percent and the Nasdaq 100 down 0.43 percent.

That kind of move usually keeps defensive healthcare names in the conversation, especially when investors compare them with other large U.S. drugmakers on the NYSE and Nasdaq.

What analysts track

For Thursday's analyst lens, the key point is the company's own investor relations page, which gives access to filings, presentations, and earnings material from Bristol Myers Squibb.

That matters for consensus work because the next published company update can reset how traders read guidance, pipeline commentary, and balance sheet language in one step.

How BMS makes money

Bristol Myers Squibb's core business comes from prescription medicines, with oncology, hematology, immunology, cardiovascular, and fibrosis treatments forming the commercial base.

Key products include Opdivo and Eliquis, two established brands that remain central to the company's revenue mix and investor discussion.

Where the stock trades today

Bristol Myers Squibb shares traded at 0 USD as of 2026-06-25 13:06 UTC in the available source set, and the NYSE listing remains the relevant venue for U.S. market reference.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.